Drug intelligence / Profile preview

RAG-24

Development stage: Preclinical
Lead developer: Ractigen Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

RAG-24 is a small activating RNA (saRNA) therapeutic candidate being developed by Ractigen Therapeutics for the treatment of obesity and related metabolic disorders. It utilizes the RNA activation (RNAa) mechanism to target gene regulatory domains and increase the expression of a specific, undisclosed endogenous therapeutic gene within adipose tissue. The drug is delivered using Ractigen's proprietary LiCO™ (lipid-conjugated oligonucleotide) technology, which facilitates targeted delivery to fat cells. RAG-24 is administered via subcutaneous injection and is currently in the discovery stage of development.

Beyond the preview

Go deeper on RAG-24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAG-24.

Explore the full profile